Repligen Joins Elite List Of Stocks With 95-Plus Composite Rating

Small but highly rated Repligen just passed another benchmark. On Friday, the IBD SmartSelect Composite Rating for Repligen (RGEN) climbed to a near-best 96, up from 90 the day before.

The new score means Waltham, Mass.-based Repligen is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. Repligen develops bioprocessing products for life sciences companies. Its stock was up 0.9% at 200.56 Friday afternoon despite the slumping overall market. It’s up about 155% from a coronavirus crash low of 78.41 on March 23, 2020.

Repligen Has Best Possible EPS Rating

The IBD Composite Rating helps investors easily measure the quality of a stock’s fundamental and technical metrics. The best growth stocks have a Composite Rating of 90 or better.

Additionally, the stock earns a 99 EPS Rating, which means its recent quarterly and annual earnings growth tops 99% of all stocks.

Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.

In Q1, the company posted 113% EPS growth to 68 cents. Revenue jumped 88% to $142.8 million, up from 56% growth the prior quarter. That marks three consecutive reports with increasing revenue and EPS gains.

Looking For The Best Stocks To Buy And Watch? Try These Screens

Repligen earns the No. 3 rank among its peers in the Medical-Products industry group. Align Technology (ALGN) is the No. 1-ranked stock within the group.

Repligen is currently forming a double-bottom base, with a 223.13 buy point. Look for the stock to break out in heavy trade at least 40% above average.


Which Companies Are Now Outperforming 95% Of All Stocks?

See Which Stocks Just Came On — And Off — IBD’s Top Stock Lists

Find Top Stocks Near A Buy Point With IBD Leaderboard

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button